RNS Reach - non-regulatory announcement

26 September 2024

Graft Polymer (UK) Plc
(the "Company")

Proactive Investors interview with Dennis Purcell

Graft Polymer (UK) PLC (LON: GPL), an innovative biotechnology company focused on co-developing therapeutics for mental health disorders, is pleased to note an interview on Proactive Investors with the Company's new Chairman, Dennis Purcell.  Mr Purcell's appointment was announced earlier today.

The interview and accompanying article can be viewed at Proactive Investors: Graft Polymer UK appoints biotechnology industry leader Dennis Purcell as Chairman.

Enquiries:

Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director. [email protected]

Allenby Capital (Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

About Graft Polymer (UK) Plc

Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders.  Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affects approximately 13 million adults in the U.S. and 20 million in US, UK, and key EU markets.

For more information, please visit www.graftpolymer.co.uk.